Finance

Beta
Lists
BAFNAPH:NSE
Bafna Pharmaceuticals Ltd
₹165.45
-5.00%
(-8.70) 1D
Jun 12, 1:05:28 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for BAFNAPH...
Open
₹179.90
High
₹179.90
Low
₹165.45
Mkt. cap
3.91B
Avg. vol.
17.82K
Volume
53.96K
P/E ratio
35.28
52-wk high
₹213.36
52-wk low
₹72.01
EPS
₹4.69
No. of employees
406
Open
₹179.90
High
₹179.90
Low
₹165.45
Mkt. cap
3.91B
Avg. vol.
17.82K
Volume
53.96K
P/E ratio
35.28
52-wk high
₹213.36
52-wk low
₹72.01
EPS
₹4.69
No. of employees
406
News stories
From sources across the web
About Bafna Pharmaceuticals Ltd
CEO-
Employees406
Founded1981
Headquarters-
SectorPharmaceutical industry
Websitebafnapharma.com
Last report
May 29, 2026
Fiscal period
Q4 2026
EPS / Est. (INR)
- / -
Revenue / Est. (INR)
422.39M / -
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
346.24M
354.68M
382.86M
422.39M
Cost of goods sold
224.18M
230.62M
272.68M
297.37M
Cost of revenue
224.18M
230.62M
272.68M
297.37M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
56.40M
54.90M
53.45M
54.43M
Operating expense
85.08M
95.97M
95.38M
106.16M
Total operating expenses
309.25M
326.59M
368.06M
403.52M
Operating income
36.99M
28.10M
14.80M
18.87M
Other non operating income
5.96M
11.80M
12.19M
17.62M
EBT including unusual items
33.89M
31.25M
18.37M
26.20M
EBT excluding unusual items
33.89M
31.25M
18.37M
26.20M
Income tax expense
-
-
-
-1.30M
Effective tax rate
-
-
-
-4.95%
Other operating expenses
14.98M
26.34M
26.23M
35.12M
Net income
33.89M
31.25M
18.37M
27.49M
Net profit margin
9.79%
8.81%
4.80%
6.51%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-9.05M
-8.64M
-8.62M
-10.29M
Net interest expenses
-9.05M
-8.64M
-8.62M
-10.29M
Depreciation and amortization charges
13.70M
14.73M
15.70M
16.60M
EBITDA
49.21M
42.31M
27.02M
34.05M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer